title: Need of stratifying patients according to severity of underlying liver disease for hepatocellular carcinoma patients undergoing systemic therapy trials.
authors.forename: W
authors.initials: W
authors.lastname: Yeo
authors.forename: F K F
authors.initials: FK
authors.lastname: Mo
authors.forename: P
authors.initials: P
authors.lastname: Hui
authors.forename: S L
authors.initials: SL
authors.lastname: Chan
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D008107:Liver Diseases / Q000503:physiopathology*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D011379:Prognosis; D020379:Risk Adjustment; D012720:Severity of Illness Index; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents